You have 9 free searches left this month | for more free features.

MDS (low and INT-1 risk as per the IPSS for MDS)

Showing 1 - 25 of >10,000

STUDY
CONDITIONS
INTERVENTIONS
LOCATIONS

Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R Trial in Canada, United States (Etavopivat)

Recruiting
  • Very Low Risk, Low Risk, or Intermediate Risk MDS Per IPSS-R
  • Ocala, Florida
  • +3 more
Jan 30, 2023

Lower Risk MDS Per IPSS-R Trial (Luspatercept)

Not yet recruiting
  • Lower Risk MDS Per IPSS-R
  • (no location specified)
Jun 21, 2023

MDS Trial in Worldwide (Oral Azacitidine, Placebo for Oral Azacitidine)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Oral Azacitidine
  • Placebo for Oral Azacitidine
  • Buenos Aires, Argentina
  • +1 more
Aug 1, 2022

Chronic Myelomonocytic Leukemia, Myelodysplastic Syndrome, Recurrent Chronic Myelomonocytic Leukemia Trial in Houston

Recruiting
  • Chronic Myelomonocytic Leukemia
  • +5 more
  • Canakinumab
  • Houston, Texas
    M D Anderson Cancer Center
Dec 7, 2022

MDS, Thrombocytopenia Trial run by the National Heart, Lung, and Blood Institute (NHLBI) (Eltrombopag)

Completed
  • Myelodysplastic Syndromes
  • Thrombocytopenia
  • Bethesda, Maryland
    National Institutes of Health Clinical Center, 9000 Rockville Pi
Mar 8, 2022

Myelodysplastic Syndrome (MDS) Trial in Worldwide (sabatolimab, azacitidine, venetoclax)

Active, not recruiting
  • Myelodysplastic Syndrome (MDS)
  • Brasschaat, Belgium
  • +9 more
Jan 19, 2023

Anemia in MDS Trial in Plantation, Bronx, Austin (TP-0184)

Completed
  • Anemia in Myelodysplastic Syndromes
  • Plantation, Florida
  • +2 more
Apr 4, 2022

AML, MDS, Old Age; Debility Trial in Suzhou (Azacitidine, all trans retinoic acid)

Recruiting
  • AML
  • +3 more
  • Suzhou, Jiangsu, China
    The First Affiliated Hospital of Soochow University
Dec 27, 2021

MDS, MDS, Thrombocytopenia Trial (Placebo, Romiplostim)

Completed
  • MDS
  • +2 more
  • Placebo
  • Romiplostim
  • (no location specified)
Nov 4, 2022

Anemia Trial (Luspatercept)

Not yet recruiting
  • Anemia
  • Luspatercept
  • (no location specified)
May 26, 2023

Low Risk MDS Trial (R906289 Monosodium (R289 Na))

Not yet recruiting
  • Low Risk Myelodysplastic Syndromes
  • R906289 Monosodium (R289 Na)
  • (no location specified)
Jul 22, 2022

Myelodysplastic Syndrome (MDS) Trial in United States (MBG453, Azacitidine, Decitabine)

Recruiting
  • Myelodysplastic Syndrome (MDS)
  • Chandler, Arizona
  • +22 more
Dec 5, 2022

MDS Trial in Beijing (Hetrombopag, Stanozolol Tablets)

Not yet recruiting
  • MDS
  • Beijing, China
    Peking Union Medical College Hospital
Sep 18, 2021

Anemia, MDS Trial in Germany (Canakinumab Injection)

Recruiting
  • Anemia
  • Myelodysplastic Syndromes
  • Canakinumab Injection
  • Berlin, Germany
  • +5 more
Nov 8, 2022

MDS Trial in Houston (Sertraline, Bone Marrow Aspirate/Biopsy)

Terminated
  • Myelodysplastic Syndromes
  • Houston, Texas
  • +1 more
May 31, 2022

MDS Trial in Worldwide (MBG453, Placebo, Hypomethylating agents)

Active, not recruiting
  • Myelodysplastic Syndromes
  • Duarte, California
  • +46 more
Jan 20, 2023

MDS Trial in France, Germany (N-Plate / romiplostim)

Completed
  • Myelodysplastic Syndromes
  • N-Plate / romiplostim
  • Annecy, France
  • +35 more
Sep 7, 2021

MDS Trial in Worldwide (Talacotuzumab, Daratumumab)

Completed
  • Myelodysplastic Syndromes
  • Saint Louis, Missouri
  • +20 more
Dec 28, 2022

MDS Trial in China, Japan (Luspatercept)

Recruiting
  • Myelodysplastic Syndromes
  • Beijing, China
  • +33 more
Aug 16, 2022

High Risk Myelodysplastic Syndrome, IPSS Risk Category Intermediate-1, Myelodysplastic Syndrome Trial in Houston (Azacitidine,

Active, not recruiting
  • High Risk Myelodysplastic Syndrome
  • +2 more
  • Houston, Texas
    M D Anderson Cancer Center
Aug 11, 2022

MDS (MDS) Trial in United Kingdom (Sodium Valproate, Bezafibrate, Medroxyprogesterone, Danazol)

Recruiting
  • Myelodysplastic Syndromes (MDS)
  • Sodium Valproate, Bezafibrate, Medroxyprogesterone
  • Danazol
  • Dudley, England, United Kingdom
  • +7 more
Aug 12, 2022

MDS Trial in Worldwide (Luspatercept, Epoetin Alfa)

Not yet recruiting
  • Myelodysplastic Syndromes
  • Luspatercept
  • Epoetin Alfa
  • Concord, California
  • +100 more
Jul 20, 2023

Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts) Trial in Worldwide (FG-4592, Placebo)

Active, not recruiting
  • Primary MDS (Very Low, Low or Intermediate IPSS-R With <5% Blasts)
  • Los Angeles, California
  • +71 more
Sep 16, 2022

Anemia Trial in Dresden (ACE-536)

Completed
  • Anemia
  • Dresden, Germany
    Acceleron Investigative Site
Apr 29, 2021